A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of TSN222 in Subjects With Advanced Solid Tumors or Lymphoma
Latest Information Update: 01 Aug 2024
At a glance
- Drugs TSN 222 (Primary)
- Indications Head and neck cancer; Lymphoma; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Tyligand Bioscience
Most Recent Events
- 16 Apr 2024 Status changed from not yet recruiting to recruiting.
- 11 May 2023 New trial record